By Kris B. Mamula, Pittsburgh Business Times


Cancer diagnostics company Cernostics announced collaboration with the Academic Medical Center in The Netherlands, which will give the Oakland company access to one of the world’s biggest Barrett’s Esophagus patient registries in the world.


Barrett’s Esophagus is a precursor to esophageal cancer, which has a five-year survival rate of just 17 percent. An estimated three million people have the condition and Cernostics will use the registry in completing clinical validation studies of its main product, which is called TissueCypher: Barrett’s.


Cernostics is developing a product that uses whole slide digital imaging technology to produce comprehensive risk prediction for the development of esophageal cancer in patients with Barrett’s Esophagus. Geisinger Health System, University of Pittsburgh and University of Pennsylvania are also part of Cernostics’ clinical collaborative network.